Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Immunomodulation and therapeutic characterization of thymosin fraction five

  • 15 Accesses

  • 5 Citations

Summary

In this report we describe the characterization of the immunomodulatory efficiency and therapeutic properties of thymosin fraction five (F5). We consistently observed the immunostimulation of T-cell activity in assays of allogeneic mixed lymphocyte response (MLR) and the development of cytotoxic effector cells in an allogeneic mixed lymphocyte tumor response-cell-mediated cytotoxicity assay (MLTR-CMC). No induction of suppressor cell activity was observed. Thymosin F5 also acted successfully as an adjuvant when admixed with irradiated tumor cells. We were unable to demonstrate either NK cell or macrophage activation by thymosin F5. Therapeutic protocols using thymosin F5 and directed against pre-existing experimental and spontaneous metastases, had a significant immunotherapeutic potential.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Ahmed A, Wong DM, Thurman GB, Low TLK, Goldstein AL, Sharkis SJ, Goldschneider I (1979) T-Lymphocyte maturation: Cell surface markers and immune function induced by T-lymphocyte cell-free products and thymosin polypeptides. Ann NY Acad Sci 332:81–94

  2. 2.

    Byrom NA, Campbell MA, Dean AJ, Timlin DM, Volkers C, Bodenham DC, Hobbs JR (1978) Thymosin-inducible lymphocytes in the peripheral blood of patients with malignant melanoma. Cancer Treat Rep 62:1769–1774

  3. 3.

    Chirigos MA (1978) In vitro and in vivo studies with thymosin. In: Chirigos MA (ed) Immune modulation and control of neoplasia by adjuvant therapy, Raven Press, New York, p 305

  4. 4.

    Chretien PB, Lipson S, Makuch R, Kenady D, Cohen M (1980) Effects of thymosin in vitro in cancer patients and correlation with clinical course after thymosin immunotherapy. Ann NY Acad Sci 332:135

  5. 5.

    Click RE, Benck L, Alter BJ (1972) Immune response in vitro. I. Cuture conditions for antibody synthesis. Cell Immunol 3:264

  6. 6.

    Cohen GH, Hooper JA, Goldstein AL (1975) Thymosin-induced differentiation of murine thymocytes in allogeneic mixed lymphocyte cultures. Ann NY Acad Sci 249:145

  7. 7.

    Costanzi JJ, Gagliano RG, Delaney F, Harris N, Thurman GB, Sakai H, Goldstein AL, Loukas D, Cohen GB, Thomson PD (1977) The effect of thymosin on patients with disseminated malignancies: A phase I study. Cancer 40:14

  8. 8.

    Dean JH, Connors R, Herbermann RB, Silva J, Oldham RK, McCoy JL (1977) The relative proliferation index as a more sensitive parameter for evaluating lymphoproliferative response of cancer patients to mitogens and alloantigens. Int J Cancer 20:359

  9. 9.

    Dillman RO, Beauregard JC, Zavanelli MI, Halliburton BL, Wormsley S, Royston I (1983) In vivo immune restoration in advanced cancer patients after administration of thymosin fraction 5 or thymosin αl. J Biòl Resp Mod 2:139

  10. 10.

    Dunn TB, Patter MJ (1957) A transplantable mast-cell neoplasm in the mouse. J Natl Cancer Inst 18:587

  11. 11.

    Goldschneider I, Ahmed A, Bollum FJ, Goldstein AL (1981) Induction of terminal deoxynucleotidyl transferase and Lyt antigens with thymosin: Identification of multiple subsets of prothymocytes in mouse bone marrow and spleen. Proc Natl Acad Sci USA 78:2469

  12. 12.

    Grossman Z, Herberman RB (1984) Hypothesis on the development of natural killer cells and their relationship to T cells. In: Herberman RB (ed) Natural cell-mediated immunity, vol 2. Academic Press, New York (in press)

  13. 13.

    Hart IR (1979) The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 97:587

  14. 14.

    Heber-Katz, Click RE (1972) Immune response in vitro. V. Role of mercaptoethanol in the mixed-leukocyte reaction. Cell Immunol 5:410

  15. 15.

    Hooper JA, McDaniel MC, Thurman GB, Cohen GC, Schulof RC, Goldstein AL (1975) Proc NY Acad Sci 249:125

  16. 16.

    Klein E, Klein G (1964) Antigenic properties of lymphomas induced by the Moloney agent. J Natl Cancer Inst 32:547

  17. 17.

    Kripke ML (1977) Latency, histology and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res 37:1395

  18. 18.

    Kripke ML, Gruys E, Fidler IJ (1978) Metastatic heterogeneity of cells from an ultraviolet light-induced murine fibrosarcoma of recent origin. Cancer Res 38:2962

  19. 19.

    Leung KH, Ehrke MJ, Mihich E (1983) Modification by biological products of the generation of suppressor cells in culture. Immunopharmacology 5:221

  20. 20.

    Low TLK, Thurman GB, McAdoo M, McClure J, Rossio JL, Naylor PH, Goldstein AL (1979) The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin α1 and polypeptide β1 from calf thymus. J Biol Chem 254:981

  21. 21.

    Low TLK, Thurman GB, Chincarini C, McClure JE, Marshall GD, Hu S-K, Goldstein AL (1981) Current status of thymosin research: Evidence for the existence of a family of thymic factors that control T-cell maturation. Ann NY Acad Sci 33:48

  22. 22.

    Marshall GD Jr, Low TLK, Thurman GB, Hu S-K, Rossio JL, Trivers G, Goldstein AL (1978) Overview of thymosin activity. Cancer Treat Rep 62:1731

  23. 23.

    Marshall GD Jr, Thurman GB, Goldstein AL (1980a) Regulation of in vitro generation of cell-mediated cytotoxicity: In vitro induction of suppressor T lymphocytes by thymosin. J Reticuloendothel Soc 28:141

  24. 24.

    Marshall GD Jr, Thurman GB, Goldstein AL (1980b) Regulation of in vitro generation of cell-mediated cytotoxicity. II. Characterization of thymosin-induced suppressor T cells. Immunopharmacology 2:301

  25. 25.

    Marshall GD Jr, Thurman GB, Rossio JL, Goldstein AL (1981) In vivo generation of suppressor T cells by thymosin in congenitally athymic nude mice. J Immunol 126:741

  26. 26.

    Mutchnick MG, Prieto JA, Schaffner JA, Weller FE (1982) Thymosin modulation of regulatory T cell function. Clin Immunol Immunopathol 23:626

  27. 27.

    Petro TM, Watson RR (1982) Resistance to L1210 mouse leukemia cells in moderately protein-malnourished Balb/c mice treated in vivo with thymosin fraction V. Cancer Res 42:2139

  28. 28.

    Primus FJ, De Martino L, MacDonald R, Hansen HJ (1978) Immunological reconstitution of T-cell deprived mice. I. Inability of thymosin to restore spleen cell mitogen and tumor allograft response. Cell Immunol 35:25

  29. 29.

    Raz A, Fogler WE, Fidler IJ (1979) The effects of experimental conditions on the expression of in vitro mediated tumor cytotoxicity mediated by murine macrophages. Cancer Immunol Immunother 7:157

  30. 30.

    Schultz RM, Woods WA, Mohr SJ, Chirigos MA (1976) Immune response of Balb/c × DBA/2F1 mice to a tumor allograft during pyran copolymer-inducer tumor enhancement. Cancer Res 36:1641–1646

  31. 31.

    Sharp JG, Anderson RW, Crouse DA, Cullan GM (1981) Effects of thymosin and thymic factors on the number and proliferative status of murine hematopoietic stem cells. In: Baum SJ, Ledney GD, Khan A (eds) Experimental hematology today, Karger, Basel, p 127

  32. 32.

    Sone S, Fidler IJ (1980) Tumor cytotoxicity of rat alveolar macrophages activated in vitro by endotoxin. J Reticuloendothel Soc 27:269

  33. 33.

    Talmadge JE, Key M, Fidler IJ (1981) Macrophage content of metastatic and nonmetastatic rodent neoplasms. J Immunol 126:2245

  34. 34.

    Talmadge JE, Benedict KL, Uithoven KA, Lenz BF (1984a) The effect of experimental conditions on the assessment of T cell immunomodulation by biological response modifiers, thymosin fraction five. Immunopharmacology 7:17

  35. 35.

    Talmadge JE, Oldham RK, Fidler IJ (1984b) Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers. J Biol Resp Mod 3:88

  36. 36.

    Wara DW, Ammann AJ (1978) Thymosin treatment of children with primary immunodeficiency disease. Transplant Proc 10:203

  37. 37.

    Wara DW, Johnson AC, Ammann AJ (1978) In vitro and in vivo effects of thymosin on T-lymphocyte function in primary immunodeficiency disease. In: Chirigos MA (ed) Immune modulation and control of neoplasia by adjuvant therapy. Raven Press, New York, p 333

  38. 38.

    Wara WM, Neely MH, Ammann AJ, Wara DW (1981) Biologic modification of immunologic parameters in head and neck cancer patients with thymosin fraction V. In: Goldstein AL, Chirigos MA (eds) Lymphokines and thymic hormones. Their potential utilization in cancer therapeutics. Raven Press, New York, p 257 (Progress in cancer research therapy, vol 20)

  39. 39.

    Wara WM, Wara DW, Neely MH, Carter SK (1982) Phase I trial of thymosin fraction V in advanced malignancies — preliminary NCOG report. In: Serrou B et al (eds) Current concepts in human immunology and cancer immunomodulation. Elsevier Biomedical, Amsterdam, p 553

  40. 40.

    Young, DW, Cottam J, Hoult JG (1977) Thymosin-like activity in fetal calf serum? Lancet II:1132

  41. 41.

    Zatz MM, Goldstein AL (1983) Enhancement of murine thymocyte cytotoxic T cell responses by thymosin. Immunopharmacology 6:65

  42. 42.

    Zatz MM, Glaser M, Seals CM, Goldstein AL (1981) Effects of combined cyclophosphamide and thymosin treatment on tumor growth and host survival in mice bearing a syngeneic tumor. In: Goldstein AL, Chirigos MA (eds) Lymphokines and thymic hormones: their potential utilization in cancer therapeutics. Raven Press, New York, p 249 (Progress in cancer research therapy, vol 20)

  43. 43.

    Zatz MM, Low TLK, Goldstein AL (1982) Role of thymosin and other thymic hormones in T-cell differentiation. In: Mihich E (ed) Biological responses in cancer: progress toward potential applications. Plenum, New York, p 219

Download references

Author information

Correspondence to James E. Talmadge.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Talmadge, J.E., Uithoven, K.A., Lenz, B.F. et al. Immunomodulation and therapeutic characterization of thymosin fraction five. Cancer Immunol Immunother 18, 185–194 (1984). https://doi.org/10.1007/BF00205510

Download citation

Keywords

  • Tumor Cell
  • Cell Activity
  • Effector Cell
  • Cytotoxicity Assay
  • Macrophage Activation